Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
IDEAYA Biosciences $92 million follow-on offering
We advised the underwriters on the SEC-registered stock offering
Novo Nordisk acquisition of Neotope Neuroscience
We advised Novo Nordisk on the acquisition
Novo Holdings investment in Availity
We advised Availity on the investment
Aligos Therapeutics $83.6 million follow-on offering
We advised the underwriters on the stock offering
Zylox-Tonbridge Medical Technology HK$2.56 billion IPO
We advised Zylox-Tonbridge Medical Technology on its IPO and HKEX listing
HUTCHMED HK$4.17 billion IPO and primary listing
The shares are listed on the Hong Kong Stock Exchange
GH Research $184 million IPO
We advised GH Research on the IPO and Nasdaq Listing
Theravance Biopharma $100.5 million follow-on offering
We advised the underwriters on the equity offering
ATAI Life Sciences $258.8 million IPO
We advised the underwriters on the IPO and Nasdaq listing
Century Therapeutics $242.7 million IPO
We advised the underwriters on the IPO and Nasdaq listing